World Biochips Market

World Biochips Market

This report analyzes the worldwide markets for Biochips in Millions of US$. The specific product segments analyzed are DNA Chips, Protein Chips, and Lab Chips. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 89 companies including many key and niche players worldwide such as Affymetrix, Applied Biosystems Group, Biomerieux, Bio-Rad Laboratories, Inc., Caliper Technologies Corp., Cepheid Inc., GE Healthcare Ltd., Takara Bio, Inc., and Zyomyx. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

BIOCHIPS MCP-1026
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A. DNA Chips I-3
B. Protein Chips I-3
C. Lab Chips I-4


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Promising Biochips Promote Biological Research II-1
Market Scenario across Products and Regions II-1
DNA Chips Lead the Application Front II-2
Probable Industry Directions II-2
Biochip Technology Boosts Personalised Medicine II-3
Biochip Technology Spreads beyond Pharma Industry II-3
Protein Chips to Shape the Future II-4
Proteomics “ Chip” into Biochip Technology II-4
Towards Increasing Minaturization II-4
European Advancements Set Diagnostic Procedures II-5
Competitive Scenario II-5
Major Participants II-5
Roche and Affymetrix Taste Success in the Diagnostics Market II-6
Growing Partnerships between Pharma and Biotech Companies II-6
Tech Giants Join the Biochip Fray II-7

2. Product Overview II-8
Biochips - Complex Blend of Biochemistry and Electronics II-8
Historical Perspective II-8
Lab-on-a-chip: An Enabled Technology II-10
Utility II-10
Evolution and Segmentation II-10
Differing Perspectives II-10
Classification of Biochips II-11
Manufacturing Systems Used in Biochip Manufacture II-12
Working of a Biochip II-12
A Functional Model II-13
Cocktail of Disparate Technically Specialized Applications II-13
Biochips: By-product of Multi-disciplinary Sciences II-13
Nanotechnology II-13
BioMEMS II-14
Microfluidics II-15
Micro Total Analysis System II-15

3. Biochip And Microarray Construction II-16
Chip Architecture II-16
Essence of a Biochip II-16
Concept of a Microarray II-16
Microarray Modules II-16
High Degree of Automation Spurs Biochips Use II-17
Microfabrication Technology in Biochips made from Polymer and
Plastics II-17
Micro-optics in Biochips II-17
Liquid Handling Through Micro-Dispensers II-18
Capillary Electrophoresis and Electrochemical Detectors II-18
Other Technologies II-18
Management of Bio-information II-18
Scanning II-18
Microarray Database Management II-19
Classification of DNA Chips II-19
General Description of Spotted cDNA Microarrays II-19
Spotted DNA Arrays II-19
Spotted cDNA Versus Spotted Oligonucleotide Arrays II-19
Limitations of Conventional cDNA Microarrays II-20
Protein Biochips II-20
General Applications of Protein Biochips II-21
Challenges in the Design of a Protein Biochip II-21
Limitations of Protein Chip Technology II-21
Advances by Companies II-22
Concluding Remarks for Protein Biochips II-22

4. Applications of Biochips II-23
Biochip Uses II-23
Biochips and Pharmaceutical Investigation II-24
Biochips and Medical Diagnostics II-24
Advantages of Biosensor Chip Technology II-25
Biochips and Forensics II-25
Biochips and Transplantation Screening II-25
Biochips and Identity Testing II-25
Biochips and Water and Environmental Testing II-25
Food Industry II-25

5. Trends II-26
Industry Characteristics II-26
New Products and Players to Drive Market II-26
Key Forces Boosting the Industry II-26
Industry Structure II-26
Industry Challenges II-27
Price Dearness Pauses Biochips Growth II-27
Current Approaches to Biochips II-27
The Business of Biochips II-27
Technological Trends II-28
Sensitivity II-28
Microfabrication II-29
Density II-29
Integrated Chips II-29
Patent Trends II-29
Patent Applications II-30
Table 1: Biochips Patent Applications (2003)-Percentage
Breakdown by Geographic Region for US, China, Japan,
Germany, South Korea, UK and Others (includes corresponding
Graph/Chart) II-30

6. Next Generation Technology II-31
Microfluidics Using CD-ROM Technology II-31

7. Product Innovations and Developments II-32
Affymetrix Introduces Complete Cytogenetic Solution II-32
Agilent Unveils 244K CGH Micro-Array II-32
Randox Unveils World’s First Protein Biochip II-32
Randox Introduces Thyroid Array Biochip II-32
Sigma Launches ChIP Kit II-33
Randox Develops Biochip for Synthetic Steroids II-33
US and Czech Scientists to Develop Biochips for Detecting Cancer II-33
febit Introduces New Geniom Biochip II-34
Agilent Introduces Additions to the HPLC-Chip Line for
Proteomics II-34
Progenika Develops BLOODchip II-35
Roche Introduces Gene Expression Services and Arrays II-35
Stratos Biosystems Develops New EC-Affinity Biochips II-35
Affymetrix Unveils Affymetrix GeneChip Command Console Software II-36
Affymetrix Introduces GeneChip Mouse and Rat Gene 1.0 ST Arrays II-36
Affymetrix Unveils Genome-Wide Human SNP Array 6.0 II-36
Caliper Life Sciences Launches High Throughput RNA Assay II-37
Applied Biosystems Unveils DNA Tools II-37
febit Launches Geniom RT Analyzer II-37
Austrian Research Center Develops New Biochip Surface II-38
Researchers Develop Biochips to Eliminate Animal Testing II-38
Progenika Biopharma Launches IBD DNA II-38
Bioident Develops New Lab-on-a-Chip Nanotiter Plate Prototype II-39
Ilochip and University of Denmark Develop a Biochip for
Faster Bird Flu Detection II-39
CombiMatrix Develops a Biochip for Leukemia Analysis II-39
Affymetrix Launches New Tiling Arrays for Mapping Whole-
Genome Transcript II-39
Roche Plans to Launch AmpliChip in Japan II-40
Caliper Life Sciences Unveils Desktop Profiler II-40
Massachusetts Institute of Technology Develops Portable Lab
on a Chip II-40
Optical Device to Develop Lab-on-a-Chip II-40
Agilent Launches Five New HPLC Chips II-41
Protagen AG Launches New Protein Biochips II-41
Fluidigm Releases the 8.96 TOPAZ Screening Chip II-41
Affymetrix Releases Chip-on-Chip Array II-41
DNA Chip Research Launches High Sensitivity DNA Chip II-41
DNA Chip Research and HitachiSoft Unveils AceGene II-41
Affymetrix Introduces GeneChip® Human Exon Array II-41
Affymetrix Announces Launch of GeneChip(R) Array Station II-42
Affymetrix Unveils GeneChip® Human Mapping 500K Arra Set II-42
Affymetrix Introduces GeneChip-Compatible™ Application Program II-42
Affymetrix Launches GeneChip(R) Scanner II-42
Hitachi Develops RFID Sensor Chip for DNA Analysis II-43
Canon Develops DNA Chip on Inkjet Printer Technology II-43
Biacore Introduces Array-Based Protein Interaction Analysis
Systems II-43
Caliper Launches Protein Express Assay for Electrophoresis
System II-43
Affymetrix Rolls Out GeneChip(R) Globin-Reduction Kits and
Protocol II-43
Biacore Introduces Next Generation System for Protein
Interaction Analysis (Sweden) II-44
Affymetrix and Invitrogen Launch Reagents for GeneChip
Expression Array Platform II-44
Amersham Biosciences Extends CodeLink Range II-44
Ciphergen Showcases ProteinChip System- Series 4000 II-44
Affymetrix Rolls Out Plasmodium/Anopheles Genome GeneChip(R)
Array II-45
SIRS-Lab Showcases Lab-Arraytor(R) II-45
Affymetrix Unveils GeneChip(R) Array for Malaria Study II-45
Caliper Extends Portfolio of LabChip Microfluidic Systems II-45
Affymetrix Launches World’s First Diagnostic Microarray
System (Europe) II-45
Ushio’s biochip Machine for BioMEM and MicroTAS (Japan) II-46
Invitrogen Unveils Yeast ProtoArray II-46
Randox Showcases biochip Technology for Clinical Diagnostics
(UK) II-46
Zyomyx Introduces Murine Cytokine Biochip (US) II-46
Invitrogen Launches ProtoArray Human Protein Microarray II-47
Affymetrix Launches Plasmodium Genome GeneChip(R) II-47

8. Recent Industry Activity II-48
DNA Chip Acquires HuBit’s Gene Analysis Business II-48
Affymetrix Acquires USB II-48
Roche NimbleGen Forms Alliance with BioDiscovery to Provide
CGH Solutions II-48
Illumina Announces Partnership with Genpathway for ChIP
Sequencing Services II-48
Jiangsu and IMDi Diagnosis to Establish Joint Venture II-49
Plexera Biosciences Enters into an Option Deal with Auguron II-49
Affymetrix and Avesthagen Enter into an Agreement II-50
Roche NimbleGen and Affymetrix Announce Expansion of License
Agreement II-50
Proteomika and Auguron Biosciences Ink Option Agreement II-50
Gentel Biosciences and Eppendorf Enter into Global License
Agreement II-51
GATC Biotech Establishes New Subsidiary II-51
Procognia Spins off Sense Proteomic II-52
Johns Hopkins University Purchases MassARRAY System II-52
Yale University Purchases MassARRAY System II-52
Korea’s NIH Extends KARE Project with Affymetrix Technology II-52
febit Obtains US Patent for Hybselect, a Microfluidic
Extraction Method II-53
Roche Takes Over NimbleGen II-53
GenTel BioSciences Acquires Protein Chip Platform Assets of GSK II-54
Advanced Liquid Logic Acquires Nanolytics II-54
Applied Microarrays Acquires Select GE Healthcare’s Assets II-54
Canon, Toshiba and Other Companies to Join Hands for Biochips II-55
BioChip Innovations Signs Research Collaboration Agreement
with IME II-55
Protagen Enters into a Partnership to Develop Antibodies II-56
Spanish Society of Rheumatology Enters into Collaboration
with Progenika II-56
Affymetrix and Partners Healthcare Extend Collaboration II-56
Agencourt, NuGEN and Affymetrix Clinical Services Collaborate II-57
Affymetrix Inks Licensing Agreement with Empire Genomics II-57
Caliper Enters into a Licensing Agreement with Monogram
Biosciences II-57
Affymetrix and IPSOGEN Sign Agreement II-58
bioMérieux and NuGEN Enter into Supply and Cross-License
Agreement II-58
VWR and CapitalBio Enter into a Distribution Agreement II-59
C3B Bags Contract from Department of Defense to Develop an
Implantable Biochip II-59
UCL Subsidiary and Roche Diagnostics Ink Licensing Deal II-59
Affymetrix Establishes the European Cytogenetic Research
Initiative II-59
Fluidigm Establishes New Development Center II-60
Daiichi Pure Chemicals Applies for Approval to Market DNA
Micro-array II-60
GE Healthcare Snaps Up Biacore II-60
Bio-Rad Acquires Ciphergen’s Life Science Research Business II-61
Sysmex to Form Partnership with Affymetrix II-61
Daiichi, Toshiba Hokuto and Toshiba Join Hands II-61
Affymetrix Collaborates with Zhejiang California Nanosystem
Institute II-61
Merck Sharp & Dohme and Shanghai Biochip Enter into Co-
operation Agreement II-62
Toshiba Signs Licensing Agreement with Antara BioSciences II-62
MUSC Signs LOI with Lumera II-62
AVIVA Inks Agreement with Japan’s Cosmo Bio II-62
Lumera Signs Collaborative Agreement with Harvard Medical
School II-63
Whatman Receives CE Mark for CombiChip II-63
IDIBAPS Led Project Receives Approval from European Union II-64
Toray to Establish DNA Chip Business II-64
Protagen Forays into the US Market II-64
Biacore Expands Operations into Chinese Market II-64
Nisshinbo to Replace Glass with Resin in DNA Production II-64
OCIMUM Acquires a Division of MWG Biotech AG II-65
Biacore Acquires FLEXChip from HTS BioSystems II-65
Qiagen Acquires Assets of LumiCyte II-65
BD Sells Clontech II-65
Affymetrix Acquires ParAllele BioScience II-65
Biacore Acquires FLEXChip System from HTS BioSystems II-66
Caliper Signs Purchase Agreement with Amphora II-66
Bio-Rad Inks Agreement with Caliper II-66
Toray Enters Joint Research Agreement with DNA Chip Research II-66
Ciphergen and Quest Diagnostics Partner for Proteomic
Diagnostic Tests II-66
Affymetrix and bioMerieux Extend Agreement II-67
bioMérieux Extend Collaboration Agreement with ExonHit
Therapeutics II-67
Agilent Technologies Licenses Caliper's LabChip(R) Technology II-67
Caliper and Predicant Biosciences Forge Licensing Agreement II-68
IntegraGen Signs Agreement with La Ligue Nationale Contre le
Cancer II-68
GSK Selects Affymetrix GeneChip® 500K Array for Whole- Genome
Association Studies II-68
Affymetrix Supplies GeneChip Technology to Veridex II-68
GE Acquires Amersham PLC II-68
ViroLogic Merges with Aclara Biosciences II-69
Invitrogen Accredits Protein Chip Intellectual Property From
Zyomyx II-69
Toshiba Collaborates with Osaka University II-69
Siemens, Infineon and Dr. Hintsche Plan Extended Alliance on
Biochip Technology II-69
Intel Eyes Biochips II-70
APAF and LumiCyte Join Hands in Proteomic Discovery II-70
Affymetrix and Caliper Life Sciences Join Forces for Target
Preparation II-70
Affymetrix and TGen Collaborate to Offer Genotyping Services II-70
Affymetrix Licenses GeneChip Technology to Veridex II-71
Affymetrix Grants Access to Aventis for GeneChip(R) Platform II-71
GeneChip Technology to Aid Neurological Disease Detection II-71
Affymetrix, ParAllele and Cambridge University Join Hands For
Extensive Genotyping II-71

9. Focus on Select Global Players II-72
Affymetrix (US) II-72
Applied Biosystems Group (US) II-72
Biomerieux (France) II-72
Bio-Rad Laboratories, Inc. (US) II-73
Caliper Technologies Corp (US) II-73
Cepheid Inc. (US) II-73
GE Healthcare Ltd (UK) II-74
Takara Bio, Inc. (Japan) II-74
Zyomyx (US) II-74

10. Global Market Perspective II-75
Table 2: World Recent Past, Current & Future Analysis for
Biochips by Geographic Region - US, Canada, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-75

Table 3: World Long-term Projections for Biochips by
Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-76

Table 4: World 10-Year Perspective for Biochips by Geographic
Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, and Rest of World Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart) II-77

Table 5: World Recent Past, Current & Future Analysis for DNA
Chips by Geographic Region - US, Canada, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-78

Table 6: World Long-term Projections for DNA Chips by
Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-79

Table 7: World 10-Year Perspective for DNA Chips by Geographic
Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, and Rest of World Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart) II-80

Table 8: World Recent Past, Current & Future Analysis for
Protein Chips by Geographic Region - US, Canada, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-81

Table 9: World Long-term Projections for Protein Chips by
Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-82

Table 10: World 10-Year Perspective for Protein Chips by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, and Rest of World Markets for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-83

Table 11: World Recent Past, Current & Future Analysis for Lab
Chips by Geographic Region - US, Canada, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-84

Table 12: World Long-term Projections for Lab Chips by
Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-85

Table 13: World 10-Year Perspective for Lab Chips by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, and Rest of World Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) II-86


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Outlook III-1
Biochips Market Overview III-1
Time Saving Biochips - All Set to Grow III-1
Multiple Applications of Biochips Drive Sales III-1
Biochip Market Faces Challenges III-2
Product Developments/Launches III-2
Strategic Corporate Developments III-10
Key Player Review III-22
Affymetrix III-22
Applied Biosystems Group III-22
Bio-Rad Laboratories, Inc. III-22
Clontech Laboratories, Inc. III-23
Caliper Life Sciences, Inc. III-23
Cepheid III-23
Zyomyx III-24
B.Market Analytics III-24
Table 14: US Recent Past, Current & Future Analysis for
Biochips by Product Segment - DNA Chips, Protein Chips and
Lab Chips Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-24

Table 15: US Long-Term Projections for Biochips by Product
Segment - DNA Chips, Protein Chips and Lab Chips Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-25

Table 16: US 10-Year Perspective for Biochips by Product
Segment - Percentage Breakdown of Dollar Sales for DNA
Chips, Protein Chips and Lab Chips Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-25

2. Canada III-26
Market Analysis III-26
Table 17: Canadian Recent Past, Current & Future Analysis
for Biochips by Product Segment - DNA Chips, Protein Chips
and Lab Chips Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-26

Table 18: Canadian Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-27

Table 19: Canadian 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-27

3. Japan III-28
A.Market Analysis III-28
DNA Chip Based on Printing Technology III-28
DNA Chips to Reveal Links Among Genes III-28
A leading Japanese Biochip Player - Takara Shuzo III-29
ICAN ™ Technology for Large-Scale Production of DNA Fragments III-29
Product Launches III-30
Strategic Corporate Developments III-30
Takara Bio Inc - A Key Player III-33
B.Market Analytics III-34
Table 20: Japanese Recent Past, Current & Future Analysis
for Biochips by Product Segment - DNA Chips, Protein Chips
and Lab Chips Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-34

Table 21: Japanese Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-35

Table 22: Japanese 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-35

4. Europe III-36
A.Market Analysis III-36
Biochips Outlook in Europe III-36
European Advancements Shape Diagnostic Procedures III-36
Product Launches III-37
Strategic Corporate Developments III-37
B.Market Analytics III-38
Table 23: European Recent Past, Current & Future Analysis
for Biochips by Geographic Region - France, Germany, UK, and
Rest of Europe Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-38

Table 24: European Long-Term Projections for Biochips by
Geographic Region - France, Germany, UK, and Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-39

Table 25: European 10-Year Perspective for Biochips by
Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, UK, and Rest of Europe Markets for
Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-40

Table 26: European Recent Past, Current & Future Analysis
for Biochips by Product Segment - DNA Chips, Protein Chips
and Lab Chips Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-41

Table 27: European Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-41

Table 28: European 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-42

4a. France III-43
A.Market Analysis III-43
Strategic Corporate Developments III-43
Biomerieux - A Major Player III-44
B.Market Analytics III-45
Table 29: French Recent Past, Current & Future Analysis for
Biochips by Product Segment - DNA Chips Protein Chips and
Lab Chips Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-45

Table 30: French Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-45

Table 31: French 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-46

4b. Germany III-47
A.Market Analysis III-47
Berlin, Brandenburg and Biochips III-47
Product Launch III-47
Strategic Corporate Developments III-48
B.Market Analytics III-49
Table 32: German Recent Past, Current & Future Analysis for
Biochips by Product Segment - DNA Chips, Protein Chips and
Lab Chips Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-49

Table 33: German Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-49

Table 34: German 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-50

4c. The United Kingdom III-51
A.Market Analysis III-51
Product Launches III-51
Strategic Corporate Developments III-52
GE Healthcare Ltd - A Key Player III-53
B.Market Analytics III-53
Table 35: UK Recent Past, Current & Future Analysis for
Biochips by Product Segment - DNA Chips, Protein Chips and
Lab Chips Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-53

Table 36: UK Long-Term Projections for Biochips by Product
Segment - DNA Chips, Protein Chips and Lab Chips Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-54

Table 37: UK 10-Year Perspective for Biochips by Product
Segment - Percentage Breakdown of Dollar Sales for DNA
Chips, Protein Chips and Lab Chips Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-54

4d. Rest of Europe III-55
A.Market Analysis III-55
Status of Proteomics in Finland III-55
Product Developments/Launches III-55
Strategic Corporate Developments III-57
B.Market Analytics III-59
Table 38: Rest of Europe Recent Past, Current & Future
Analysis for Biochips by Product Segment - DNA Chips Protein
Chips and Lab Chips Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-59

Table 39: Rest of Europe Long-Term Projections for Biochips
by Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-60

Table 40: Rest of Europe10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-61

5. Rest of World III-62
A.Market Analysis III-62
China III-62
Basic Environment and Commercial Development III-62
Biochip Research III-62
Status of Biochip Industry in China III-63
Historic Review - Chinese Government Chips in III-63
Novel Technologies - Top on China’s Agenda III-64
Taiwan III-64
Taiwan Pursues Promise of Biochip Sector III-64
International Advantage Sought III-64
Strategic Corporate Developments III-65
B.Market Analytics III-69
Table 41: Rest of World Recent Past, Current & Future
Analysis for Biochips by Product Segment - DNA Chips
Protein Chips and Lab Chips Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-69

Table 42: Rest of World Long-Term Projections for Biochips
by Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-70

Table 43: Rest of World 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-71


IV. COMPETITIVE LANDSCAPE